ALLMedicine™ Indolent Lymphoma Center
Research & Reviews 178 results
https://clinicaltrials.gov/ct2/show/NCT04933617
May 13th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...
https://doi.org/10.1097/MD.0000000000029219
Medicine Wang M, Guo Y et. al.
May 6th, 2022 - Nodal marginal zone B-cell lymphoma (NMZL) is a relatively rare indolent lymphoma that is the least common subtype of marginal zone B-cell lymphoma. Furthermore, coexistence of lymphoma and multiple myeloma (MM) is rare. Here, we report a case of ...
https://clinicaltrials.gov/ct2/show/NCT05326243
Apr 13th, 2022 - Cluster of differentiation (CD) 19 chimeric antigen receptor T-cell (CAR-T) has been a very promising treatment option for multiple types of B-cell lymphoma. Kymriah® (tisagenlecleucel, Novartis) and Yescarta® (axicabtagene ciloleucel, Gilead) wer...
https://doi.org/10.1093/oncolo/oyac054
The Oncologist; Bouchkouj N, Zimmerman M et. al.
Apr 12th, 2022 - In March 2021, the U.S. Food and Drug Administration granted accelerated approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymp...
https://doi.org/10.1111/bjh.18161
British Journal of Haematology; Hess G, Hüttmann A et. al.
Apr 2nd, 2022 - The prognosis of patients with relapsed diffuse large B-cell lymphoma (DLBCL) remains poor with current options. Here we prospectively evaluated the combination of pixantrone with obinutuzumab for up to six cycles for patients with relapsed or ref...
Guidelines 1 results
https://doi.org/10.1007/s12094-010-0592-7
Clinical & Translational Oncology : Official Publication ... Rodríguez-Abreu D, Llanos Muñoz M et. al.
Oct 27th, 2010 - Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin's lymphoma (NHL) in the Western world. FL constitutes the most frequent indolent lymphoma, well characterized by its clinical presentation related to nodal involvement and i...
Drugs 1 results see all →
Clinicaltrials.gov 15 results
https://clinicaltrials.gov/ct2/show/NCT04933617
May 13th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...
https://clinicaltrials.gov/ct2/show/NCT05326243
Apr 13th, 2022 - Cluster of differentiation (CD) 19 chimeric antigen receptor T-cell (CAR-T) has been a very promising treatment option for multiple types of B-cell lymphoma. Kymriah® (tisagenlecleucel, Novartis) and Yescarta® (axicabtagene ciloleucel, Gilead) wer...
https://clinicaltrials.gov/ct2/show/NCT05073250
Feb 22nd, 2022 - Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are the most common inert non Hodgkin's lymphoma (iNHL). Their natural courses are slow but highly variable. The standard first-line treatment of advanced FL / MZL is based on rituximab. Wh...
https://clinicaltrials.gov/ct2/show/NCT05020678
Jan 21st, 2022 - This is a dose-finding study of NKX019 and will be conducted in 2 parts: Part 1: dose finding utilizing a "3+3" enrollment schema. Part 2: dose expansion to further evaluate safety and tolerability, cellular kinetics, pharmacodynamics and anti-tum...
https://clinicaltrials.gov/ct2/show/NCT02953509
Jan 5th, 2022 - The primary objectives of this study are: To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, ge...
News 63 results
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl
May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types
Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....
https://www.onclive.com/view/inside-the-clinic-jtcc-experts-highlight-next-steps-with-car-t-cell-therapy
Mar 9th, 2022 - Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, and Andre H. Goy, MD, physician in chief of the Hackensack...
https://www.onclive.com/view/btk-inhibitors-pi3k-inhibitors-and-car-t-cell-therapy-shake-up-hematologic-malignancies-armamentarium
Nov 15th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...
https://www.onclive.com/view/numerous-drug-classes-studied-for-use-in-follicular-lymphoma
Oct 6th, 2021 - Bruce D. Cheson, MD Follicular lymphoma (FL) is characterized by repeated treatment responses and then relapses, and until more effective frontline therapies become available, researchers will need to generate a growing list of drug choices to ke...
